IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

Immunovant, Inc. (IMVT) reported third-quarter fiscal 2025 net loss of 76 cents per share, wider than the Zacks Consensus Estimate of a loss of 73 cents. The reported figure is also wider than the year-ago quarter's loss of 36 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.Currently, Immunovant does not have any approved product in its portfolio. As a result, it is yet to generate revenues.The stock declined 9.6% following the lower-than-expected earnings results.IMVT’s ...